[{"id":"c5cbefb4-2b0f-4701-a9a1-8be7116f6272","acronym":"","url":"https://clinicaltrials.gov/study/NCT01018979","created_at":"2021-01-18T03:59:46.250Z","updated_at":"2024-07-02T16:36:30.431Z","phase":"Phase 2","brief_title":"Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients","source_id_and_acronym":"NCT01018979","lead_sponsor":"GPCR Therapeutics, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e burixafor (GPC-100)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 02/01/2010","start_date":" 02/01/2010","primary_txt":" Primary completion: 10/01/2011","primary_completion_date":" 10/01/2011","study_txt":" Completion: 10/01/2011","study_completion_date":" 10/01/2011","last_update_posted":"2021-05-11"},{"id":"7de24069-d0e2-4dc0-9608-66a93029fa5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02104427","created_at":"2021-01-18T09:43:26.119Z","updated_at":"2024-07-02T16:36:31.554Z","phase":"Phase 2","brief_title":"PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients","source_id_and_acronym":"NCT02104427","lead_sponsor":"GPCR Therapeutics, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e burixafor (GPC-100)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2021-04-19"},{"id":"98650662-105e-4826-8b8e-4e5e0cb66828","acronym":"","url":"https://clinicaltrials.gov/study/NCT01458288","created_at":"2021-01-18T06:03:35.087Z","updated_at":"2024-07-02T16:36:31.894Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease","source_id_and_acronym":"NCT01458288","lead_sponsor":"GPCR Therapeutics, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e burixafor (GPC-100)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2021-04-19"}]